AT-1002|CAS 835872-35-0|DC Chemicals

Cas No.:	835872-35-0
Chemical Name:	AT-1002
Synonyms:	AT-1002;AT 1002;AT1002
SMILES:	NC(=N)NCCCC(NC(=O)CNC(=O)C(C(C)CC)NC(=O)C(CS)NC(=O)C(N)CC1=CC=CC=C1)C(=O)NC(CC(C)C)C(O)=O
Formula:	C₃₂H₅₃N₉O₇S
M.Wt:	707.88
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication:	[1]. Li M, et al. Structure-activity relationship studies of permeability modulating peptide AT-1002. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4584-6. [2]. Gopalakrishnan S, et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm. 2009 Jan 5;365(1-2):121-30.

Description:	AT-1002, a 6-mer synthetic peptide[1], is a tight junction regulator and absorption enhancer[2].
In Vitro:	AT-1002 a 6-mer synthetic peptide belongs to an emerging novel class of compounds that reversibly increase paracellular transport of molecules across the epithelial barrier. AT-1002 can undergo Cys-Cys dimerization[1]. Undifferentiated Caco-2 cells are treated with AT-1002 and viability is assessed by measuring cellular ATP content. Treatment with AT-1002 for up to 3 h does not affect cell viability at any concentration. In particular, the viability of Caco-2 cells is not affected by 5 mg/mL AT-1002. AT-1002 reduces cell viability after 24 h at concentrations of 2.5 mg/mL and higher. However, the cells remain viable after 24 h if the cells are washed after exposure to AT-1002 for 3 h indicating that AT-1002 does not irreversibly damage cells[2]. AT-1002 treatment results in 3-fold increase in phosphotyrosine content of zonula occludens-1 (ZO-1)[2].
References:	[1]. Li M, et al. Structure-activity relationship studies of permeability modulating peptide AT-1002. Bioorg Med Chem Lett. 2008 Aug 15;18(16):4584-6. [2]. Gopalakrishnan S, et al. Mechanism of action of ZOT-derived peptide AT-1002, a tight junction regulator and absorption enhancer. Int J Pharm. 2009 Jan 5;365(1-2):121-30.

Cat. No.	Product name	Field of application
DC31074	Isopropyl myristate	Isopropyl myristate is the ester of isopropyl alcohol and myristic acid.
DC75868	AZ14133346	AZ14133346 (compound 36) is a potent and selective inhibitor of EGFR Exon20 insertions, with the IC50 of 85 nM. AZ14133346 plays an important role in cancer research.
DC75865	TI17	TI17 represents a novel class of targeted anticancer agents that specifically disrupt DNA damage repair mechanisms in malignant cells.
DC75816	Nisoxetine	Nisoxetine acts as a highly selective and potent noradrenaline transporter (NET) antagonist, exhibiting a binding affinity (Kd) of 0.76 nM. In addition to its antidepressant properties, nisoxetine functions as a local anesthetic by inhibiting voltage-gated sodium channels. This dual pharmacological activity makes it a compound of interest for both neurological and pain management research.
DC75641	GENZ-644282 TFA salt	Genz-644282, also known as SAR402674, is a non-camptothecin inhibitor of topoisomerase I with potential antineoplastic activity. Topoisomerase I inhibitor Genz-644282 binds to and inhibits the enzyme topoisomerase I, which may result in the inhibition of repair of single-strand DNA breaks, DNA replication, and tumor cell growth in susceptible tumor cell populations.
DC75325	PSMA-617 TFA	PSMA-617, also know as vipivotide tetraxetan, is a ligand used to make 177Lu-PSMA-617, which is a radioactive molecule to fight cancer. PSMA617 possesses a small peptide, which was designed to target prostate-specific membrane antigen (PSMA). PSMA617 demonstrates high radiolytic stability for at least 72 h. PSMA617 has high inhibition potency (equilibrium dissociation constant Ki=2.34±2.94 nM on LNCaP; Ki=0.37±0.21 nM enzymatically determined). 177 Lu-PSMA-617 offers a potential additional life-prolonging treatment option for men with mCRPC.
DC75202	Fosaprepitant free acid	Fosaprepitant, also known as MK0517, is an antiemetic drug, administered intravenously. It is a prodrug of aprepitant. Fosaprepitant was developed by Merck & Co. and was approved. It is a prodrug of Aprepitant. It aids in the prevention of acute and delayed nausea and vomiting associated with chemotherapy treatment. Fosaprepitant is a weak inhibitor of CYP3A4, and aprepitant, the active moiety, is a substrate, inhibitor, and inducer of CYP3A4
DC74748	O4I4	O4I4 (compound 23) is a OCT4-inducing compound with metabolical stability.
DC74684	ZH8667	ZH8667 is a trace amine-associated receptor 1 (TAAR1)–Gs agonist.
DC74646	EB-PSMA-617	EB-PSMA-617 is an Evans blue-modified prostate-specific membrane antigen (PSMA) 617 ligand for making 177Lu-EB-PSMA, which is potential useful for Metastatic Castration-Resistant Prostate Cancer.